Drug intelligence / Profile preview

MVR-EX104

Development stage: Unknown
Lead developer: ImmVira
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MVR-EX104 is an investigational exosome-based therapy developed by Shenzhen Yinuowei Medical Technology. It is currently in the discovery phase and is being explored for the treatment of alopecia, a condition characterized by hair loss. The drug falls under the therapeutic areas of skin and musculoskeletal diseases. As an exosome therapy, it likely leverages cell-derived vesicles to deliver bioactive molecules that may modulate cellular processes involved in hair growth or follicle health, though specific mechanistic details have not been disclosed[1][3][4].

Beyond the preview

Go deeper on MVR-EX104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVR-EX104.

Explore the full profile